GlucoVista, a medical device company with U.S. headquarters in Fairfield, New Jersey, has raised more than $2 million as it seeks to advance a noninvasive, continuous glucose monitoring tool for Type 1 and Type 2 diabetes patients. Its technology involves using a wearable and infrared light with a companion app.
A brief description of its technology on its website states:
The CGM-305 is a wearable, continuous non-invasive glucometer that reports the glucose level in the blood by capturing the natural thermal infra-red radiation emitted from the glucose in the blood of a human body in specific wave-lengths. This methodology of glucose monitoring is totally passive, thereby providing true non-invasive glucose testing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It has raised $2.7 million from six investors, according to a Form D filing with the U.S. Securities and Exchange Commission. The company is currently conducting clinical studies with hospitals in Israel. Although
Noninvasive glucose monitoring is one of the holy grails of med tech, particularly through spectroscopy. The idea is that if companies can develop a pain-free and continuous way to measure blood-glucose levels, it would make managing the condition easier because it would become more of a passive exercise.
The overarching goal is to offer a way to help patients better manage their condition to avoid complications, hospitalization and reduce healthcare costs.
Many companies have attempted it and are in various stages of pursuing it but not one of them has yet received 510(k) clearance from the U.S. Food and Drug Administration. Among the companies in pursuit of getting noninvasive approaches approved are Integrity Applications’ GlucoTrack andSocrates Health Solutions, which use ear clips as part of their blood glucose monitoring tools. Grove Instruments is another company that has been active in this area, although I could not find an up to date website for the business.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
